Algeta ASA : Algeta ASA : New data and analyses from clinical trials of Xofigo® (radium-223 dichloride) to be presented at

   Algeta ASA : Algeta ASA : New data and analyses from clinical trials of
           Xofigo® (radium-223 dichloride) to be presented at ASCO

Not Intended for US Media

Oslo, Norway, 16 May 2013 - Algeta ASA (OSE: ALGETA) announces that further
analyses of data subsets from the phase III ALSYMPCA study of the recently
FDA-approved Xofigo^® (radium 223 dichloride, radium 223) will be presented at
the 49^th Annual Meeting of the American Society of Clinical Oncology (ASCO),
31 May-4 June, in Chicago, IL (USA).

Hematologic safety  of  Ra-223  dichloride  (Ra-223)  in  castration-resistant 
prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA
trial

  *Abstract #5060, General Poster Session: Genitourinary (Prostate) Cancer

  *Monday, 3 June, 8:00am - 11:45am, S Hall A2

Efficacy and safety of radium-223 dichloride (Ra-223) in  castration-resistant 
prostate cancer  (CRPC) patients  with  bone metastases  who  did or  did  not 
receive prior docetaxel (D) in the phase 3 ALSYMPCA trial

  *Abstract #5068, General Poster Session: Genitourinary (Prostate) Cancer

  *Monday, 3 June, 8:00am - 11:45am, S Hall A2

Pain analysis  from the  phase  3 randomized  ALSYMPCA study  with  radium-223 
dichloride (Ra-223) in  castration-resistant prostate  cancer (CRPC)  patients 
with bone metastases

  *Abstract #5038, General Poster Session: Genitourinary (Prostate) Cancer

  *Monday, 3 June, 8:00am - 11:45am, S Hall A2

Correlation  between  baseline  variables  and  survival  in  the   radium-223 
dichloride (Ra-223)  phase III  ALSYMPCA  trial with  attention to  total  ALP 
changes

  *Abstract #5080, General Poster Session: Genitourinary (Prostate) Cancer

  *Monday, 3 June, 8:00am - 11:45am, S Hall A2

About Xofigo^® (radium 223 dichloride)

Xofigo^® with the active ingredient radium  223 dichloride (radium 223) is  an 
alpha particle-emitting  radioactive  therapeutic  agent  with  an  anti-tumor 
effect on bone metastases. Radium 223 mimics calcium and forms complexes  with 
the bone mineral hydroxyapatite at areas  of increased bone turnover, such  as 
bone metastases. The high linear energy  transfer of alpha emitters may  cause 
double-strand DNA breaks in adjacent cells, resulting in an anti-tumor  effect 
on bone metastases. The alpha particle range from radium 223 is less than  100 
micrometers, which may limit the damage to the surrounding normal tissue.

In September 2009, Algeta signed an  agreement with Bayer for the  development 
and commercialization of radium 223. Under  the terms of the agreement,  Bayer 
will develop, apply for health authority approvals worldwide and commercialize
radium 223 globally. Algeta US, LLC  will co-promote radium 223 with Bayer  in 
the US.

Radium 223 is currently not approved by the European Medicines Agency (EMA) or
other authorities outside  the US. Bayer  submitted a Marketing  Authorization 
Application to the EMA for  radium 223 in December  2012 for the treatment  of 
CRPC patients with bone metastases.

For full prescribing information visit www.xofigo-us.com. 

                                     ###

Xofigo^® is a registered trademark of Bayer.

For further information about Algeta, please contact:

Mike Booth / Renate Birkeli        +47 23 00 67 32
Communications & Corporate Affairs ir@algeta.com
Media enquiries:
Mark Swallow                       +44 207 638 9571
Citigate Dewe Rogerson             mark.swallow@citigatedr.co.uk
Knut Ekern                         +47 22 04 82 00
Gambit Hill & Knowlton             knut.ekern@hkstrategies.com
Investor enquiries:
Tricia Swanson                     +1 646 378 2953
The Trout Group                    tswanson@troutgroup.com

About Algeta

Algeta is  a  company  focused  on developing  novel  targeted  therapies  for 
patients with cancer based on  its alpha-pharmaceutical platform. The  Company 
is headquartered in  Oslo, Norway, and  has a US  subsidiary, Algeta US,  LLC, 
based in Cambridge, MA performing  commercial marketing operations in the  US. 
Algeta is  listed  on the  Oslo  Stock  Exchange (Ticker:  ALGETA).  For  more 
information please visit www.algeta.com.

Forward-looking Statements



This news release contains certain  forward-looking statements that are  based 
on uncertainty, as they relate to events and depend on circumstances that will
occur in the future and which, by their nature, may have an impact on  results 
of operations  and the  financial condition  of Algeta.  Such  forward-looking 
statements reflect  our  current  views  and  are  based  on  the  information 
currently available to Algeta. Algeta cannot give any assurance as to  whether 
such forward  looking  statements will  prove  to be  correct.  These  forward 
looking statements include statements  regarding our anticipated  co-promotion 
of Xofigo in the US.  There are a number of  factors that could cause  actual 
results and developments to differ materially from those expressed or  implied 
by these  forward-looking  statements.  These  factors  include,  among  other 
things, risks or  uncertainties associated  with the ability  to identify  and 
hire a sufficient number of qualified employees in the US, growth  management, 
general economic  and business  conditions and  the pricing  environment,  the 
impact of competition, the ability  to successfully commercialize Xofigo,  the 
risk that costs associated with the co-promotion of Xofigo may be greater than
anticipated, manufacturing capacity, the risk  of non-approval of patents  not 
yet granted, risks in obtaining additional regulatory approvals for radium 223
and the other risks and uncertainties described in our annual report.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Press release

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE
HUG#1702354
 
Press spacebar to pause and continue. Press esc to stop.